|Day's range||2.36 - 2.50|
|52-week range||2.10 - 5.25|
|PE ratio (TTM)||-4.31|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|
November 7, 2016 New Leadership Focused on Increasing Commercial Potential of Proven Durasert™ Sustained Release Platform Company Continues Focus on MAA and NDA Filings for Uveitis Product in 2017 Conference ...
October 31, 2016 WATERTOWN, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug delivery products primarily for treating ...
October 4, 2016 Study is the Second of Two Ongoing Phase 3 Trials in Support Of Product Registration in the US EU Filing Remains on Track for 1Q2017 Filing WATERTOWN, Mass., Oct. 04, 2016 (GLOBE NEWSWIRE) ...